Table 2. Ongoing phase III and phase II studies on nccRCC.

Study ID	Arm A	Arm B	Inclusion Criteria	Primary outcome	Other outcomes
NCT03091192 (SAVOIR), phase III	Savolitinib	Sunitinib	MET driven pRCC	PFS	OS/ORR
NCT02761057 (PAPMET), phase II	Cabozantinib	Sunitinib; Savolitinib; Crizotinib	pRCC	PFS	OS/ORR
NCT03354884 (BONSAI), phase II	Cabozantinib	–	CDC	ORR	PFS/OS
NCT03075423 (SUNNIFORECAST), phase II	Nivolumab, Ipilimumab	Sunitinib	nccRCC	12 months OS	PFS/ORR/OS
NCT02724878, phase II	Atezolizumab, Bevacizumab	–	nccRCC	ORR	PFS/OS
NCT02915783, phase II	Everolimus, Lenvatinib	–	nccRCC	ORR	PFS/OS
NCT02819596 (CALYPSO), phase II	Savolitinib, Durvalumab, Tremelimumab	–	nccRCC, ccRCC	Safety/ORR	PFS/OS
NCT03635892, phase II	Cabozantinib, Nivolumab	–	nccRCC	ORR	PFS/OS

nccRCC, non-clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma; MET, mesenchymal-epithelial transition receptor; CDC, collecting duct carcinoma; ORR, objective response rate; PFS, progression free survival; OS, overall survival.